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Serotonin is a neurotransmitter with broad functions in brain development, neuronal activ-
ity, and behaviors; and serotonin is the prominent drug target in several major neuropsychi-
atric diseases.Themultiple actions of serotonin aremediated by diverse serotonin receptor
subtypes and associated signaling pathways. However, the key signaling components that
mediate speciﬁc function of serotonin neurotransmission have not been fully identiﬁed.
This reviewwill provide evidence from biochemical, pharmacological, and animal behavioral
studies showing that serotonin regulates the activation states of brain glycogen synthase
kinase-3 (GSK3) via type 1 and type 2 serotonin receptors. In return, GSK3 directly interacts
with serotonin receptors in a highly selective manner, with a prominent effect on modu-
lating serotonin 1B receptor activity. Therefore, GSK3 acts as an intermediate modulator
in the serotonin neurotransmission system, and balanced GSK3 activity is essential for
serotonin-regulated brain function and behaviors. Particularly important, several classes
of serotonin-modulating drugs, such as antidepressants and atypical antipsychotics, reg-
ulate GSK3 by inhibiting its activity in brain, which reinforces the importance of GSK3
as a potential therapeutic target in neuropsychiatric diseases associated with abnormal
serotonin function.
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SEROTONIN NEUROTRANSMISSION
SEROTONIN
Serotonin (5-hydroxytryptamine, 5-HT) is amonoaminergic neu-
rotransmitter that is synthesized from the amino acid tryptophan.
Serotonergic neurons arise from the raphe nucleus of the brain
stem, and they project upward to most areas of the brain and
downward to peripheral nerve terminals. Upon release, 5-HT in
the synapse is recycled by reuptake through the 5-HT transporter
(5-HTT) and is catabolized by monoamine oxidase (MAO). There
are at least 7 families and 14 subtypes of 5-HT receptors that are
classiﬁed by their sequence homology and associated type of G-
proteins and signal transduction pathways (Hoyer and Martin,
1997; Bockaert et al., 2006; Table 1). Among these 5-HT receptors,
the type 1 (5-HT1) and the type 2 (5-HT2) receptors are the most
studied, with rich literatures showing their roles in brain function
and diseases (Hannon and Hoyer, 2008).
SEROTONIN TYPE 1A (5-HT1A) RECEPTORS
5-HT1A receptors are the prototypical 5-HT1 receptors. In addi-
tion to coupling to the inhibitory G-protein (Gi) that inhibits
adenylyl cyclase, decreases cyclic AMP (cAMP) production, and
inactivates protein kinase A (PKA; De Vivo and Maayani, 1986),
studies in neurons reveal that 5-HT1A receptors also regulate other
protein kinases, such as growth factor-associated Akt and extra-
cellular signal-regulated kinases (Erk; Cowen et al., 1996, 2005).
5-HT1A receptors are widely distributed in major brain areas
including the dorsal raphe nucleus, cerebral cortex, hippocampus,
striatum, and nucleus accumbens (Varnas et al., 2004). In 5-HT
neurons, 5-HT1A autoreceptors are located in the cell bodies and
somatodendrites, and activation of these receptors reduces neuron
ﬁring and suppresses 5-HT release (Riad et al., 2000). In non-
serotonergic neurons, 5-HT1A heteroreceptors are found in both
pre- and post-synaptic locations (Hoyer et al., 2002). Depending
on the location and associated neurons, activation of 5-HT1A het-
eroreceptors modulates neurotransmission of glutamate, GABA,
norepinephrine, and acetylcholine (Fink and Gothert, 2007), gen-
erally causing inhibition of long-termpotentiation (Edagawa et al.,
1998; Tachibana et al., 2004), increased axonal and dendritic
branching (Yan et al., 1997), and postnatal neurogenesis (Banasr
et al., 2004). 5-HT1A receptors mediate many behavioral effects
of 5-HT, particularly those related to mood and anxiety (Kennett
et al., 1987; Parks et al., 1998).
SEROTONIN TYPE 1B (5-HT1B) RECEPTORS
The rodent 5-HT1B receptors and its human homolog 5-HT1D
receptors share high protein sequence homology and signal trans-
duction processes with 5-HT1A receptors, and 5-HT1B receptors
also act as both autoreceptors and heteroreceptors in the brain
(Bouhelal et al., 1988; Hoyer and Martin, 1997; Leone et al., 2000;
Bockaert et al., 2006). Different from 5-HT1A autoreceptors, 5-
HT1B autoreceptors are primarily located on the 5-HT neuron
axon terminals that extend to other brain regions. Upon activa-
tion, 5-HT1B autoreceptors cause a strong feedback inhibition of
5-HT release (Riad et al., 2000). 5-HT1B receptors also act as het-
eroreceptors in several brain regions to control release of other
neurotransmitters (Sari, 2004). Both 5-HT1B receptor agonists
and antagonists may have antidepressant effects; blocking autore-
ceptors increases extracellular 5-HT which enhances the effect of
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Table 1 | Serotonin receptors.
Family Subtypes Classical signal transduction
5-HT1 1A, 1B, 1D, 1E, 1F Gi/Go-protein coupled Inhibit AC, reduce cAMP, inhibit PKA
5-HT2 2A, 2B, 2C Gq/G11-protein coupled Increase IP3, increase intracellular calcium, increase DAG, activate PKC
5-HT3 Ligand-gated Na+ and K+ cation channel Membrane depolarization
5-HT4 Gs-protein coupled Activate AC, increase cAMP, activate PKA
5-HT5 5A, 5B Gi/Go-protein coupled Inhibit AC, reduce cAMP, inhibit PKA
5-HT6 Gs-protein coupled Activate AC, increase cAMP, activate PKA
5-HT7 Gs-protein coupled Activate AC, increase cAMP, activate PKA
serotonin-reuptake inhibitors (Dawson et al., 2006), whereas acti-
vation of heteroreceptors contributes to an antidepressant effect,
potentially through their effects on dopaminergic neurotrans-
mission (Chenu et al., 2008). Recently, 5-HT1B receptors have
been found to interact with an intracellular adaptor protein p11
(Svenningsson et al., 2006), which regulates 5-HT1BR activity and
stability, and deletion of which causes depression-like behaviors
in animals (Svenningsson and Greengard, 2007).
SEROTONIN TYPE 2A (5-HT2A) RECEPTORS
5-HT2A receptors are the prototypical type 2 5-HT receptors that
couple to Gq protein to activate phospholipase C (PLC) and its
down-stream targets such as protein kinase C (PKC; Conn and
Sanders-Bush, 1984; Roth et al., 1986; Takuwa et al., 1989). 5-
HT2A receptors have also been reported to activate Akt and Erk
(Watts, 1998; Johnson-Farley et al., 2005; Zhong et al., 2008),
although the receptor-coupling mechanism of this regulation is
not completely understood. 5-HT2A receptors also couple to
the intracellular scaffolding protein β-arrestin2, which may have
unique functions to initiate desensitization of 5-HT2A recep-
tors and to direct ligand-selective signal transduction processes
(Schmid et al., 2008; Schmid and Bohn, 2010). 5-HT2A receptors
are expressed throughout the brain,most prominently in the cere-
bral cortex, striatum, and hippocampus (Bockaert et al., 2006),
where they are located on soma, dendrites, and axons of pyra-
midal neurons, interneurons, and monoaminergic neurons (Jakab
andGoldman-Rakic,1998;Cornea-Hebert et al., 1999;Hoyer et al.,
2002; Miner et al., 2003). Activation of 5-HT2A receptors modu-
lates levels of other neurotransmitters, such as causing inhibitory
control over dopamine release (Schmidt and Fadayel, 1995). In
many studies, 5-HT2A receptors are found to counteract the phys-
iological and behavioral effects of 5-HT1A receptors (Marek et al.,
2003). For example, Yuen et al. (2008) reported that activation of
5-HT2A/C receptors in prefrontal cortical neurons signiﬁcantly
attenuates the effect of 5-HT1A receptors on NMDA currents and
microtubule depolymerization. 5-HT2A receptors have a different
behavioral proﬁle as 5-HT1A receptors. Most notably, a group of
5-HT2A receptor agonists are hallucinogens (Nichols, 2004), but
5-HT2A receptors also have signiﬁcant effects in regulating other
neuropsychiatric behaviors, such as mood, cognition, and sleep
(Landolt and Wehrle, 2009).
THERAPEUTIC IMPLICATIONS OF 5-HT MODULATORS
For decades, modulation of 5-HT neurotransmission has been
the primary pharmacological target for the treatment of major
neuropsychiatric diseases, particularly depression and anxiety.
The monoamine oxidase inhibitors (MAOI) enhance 5-HT neu-
rotransmission by blocking 5-HT metabolism (Youdim and
Bakhle, 2006), while tricyclic antidepressants (TCA; Klerman and
Cole, 1965), serotonin-selective reuptake inhibitors (SSRI), and
serotonin–norepinephrine reuptake inhibitors (SNRI) all enhance
synaptic 5-HT action by blocking reuptake of 5-HT. Global
enhancement of serotonin neurotransmission may activate all
subtypes of serotonin receptors in brain, while each 5-HT recep-
tor subtype has different and speciﬁc functions in deﬁned brain
regions.Activationof 5-HT1Areceptors is thought to contribute to
the effect of antidepressants in regulatingmood and anxiety (Parks
et al., 1998;Ramboz et al., 1998; Leonardo andHen,2008;Akimova
et al., 2009; Savitz et al., 2009;Polter andLi,2010;Price andDrevets,
2010), whereas acute activation-induced down-regulation of 5-
HT1A autoreceptors may be necessary for the antidepressant and
anxiolytic effects during long-term 5-HT reuptake inhibitor treat-
ment (Blier and Ward, 2003; Albert and Lemonde, 2004). The
speciﬁc roles of other 5-HT receptor subtype in the antidepressant
action remain to be largely unknown.
In addition to enhancing 5-HT neurotransmission for treat-
ment of anxiety and depression, agents with 5-HT2A receptor
antagonistic property appear to have a unique role in treat-
ing neuropsychiatric diseases. Several antidepressants, including
mirtazapine, nefazodone, and trazodone have 5-HT2A receptor
antagonistic properties thatmay contribute to their unique antide-
pressant effect. Atypical antipsychotics not only are antagonists of
dopamine D2 receptors (as with the conventional antipsychotics),
but they also block 5-HT2A and 5-HT2C receptors (Meltzer
et al., 1989; Markowitz et al., 1999). In addition to treating psy-
chosis, most atypical antipsychotics have indications for bipolar
mania, and somehave shown efﬁcacy in ameliorating symptomsof
depression (Tohen et al., 2003; Calabrese et al., 2005; Berman et al.,
2007; Marcus et al., 2008; Bauer et al., 2009). Although the exact
mechanism remains to be unknown, facilitating dopamine and
norepinephrine neurotransmission (Schmidt and Fadayel, 1995;
Zhang et al., 2000) and/or enhancing 5-HT1A receptor action
(Marek et al., 2003) may contribute to this therapeutically relevant
action of 5-HT2A receptor antagonists.
The brain’s serotonergic system is highly complex, in part due
to its diffusely distributed multiple receptor subtypes and the sig-
nal transduction pathways regulated by these receptors. Therefore,
identifying intracellular signaling molecules that direct 5-HT-
regulated signals to speciﬁc physiological and behavioral effects
may facilitate our understanding of brain 5-HT function and its
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role in neuropsychiatric diseases. Below we review current ﬁnd-
ings on the interrelationship between 5-HT and glycogen synthase
kinase-3 (GSK3), with an emphasis on the type 1 and type 2 5-HT
receptors.
EFFECTS OF 5-HT ON REGULATING GSK3
5-HT REGULATES GSK3 BY PHOSPHORYLATION
5-hydroxytryptamine was ﬁrst found to regulate GSK3 in mouse
brain. When wild type mice received an acute administration of
d-fenﬂuramine, a drug that enhances 5-HT release and blocks
5-HT reuptake, phosphorylation of GSK3β at serine-9 residue
was signiﬁcantly increased in the cerebral cortex, hippocampus,
and striatum (Li et al., 2004). Phosphorylation of this residue
transforms the N-terminal of GSK3 into a pseudosubstrate which
blocks other GSK3 substrates from entering the active site of the
enzyme, thus, d-fenﬂuramine treatment results in inhibition of
GSK3β in the brain. However, even in the presence of a MAOI that
blocks the metabolism of 5-HT, the effect of a single intraperi-
toneal injection of d-fenﬂuramine is transient, peaking at 1 h, and
gradually returning to baseline level by 4 h. This could be due to
rapid metabolism of the drug in mice, but rapid release of 5-HT
may cause negative feedback inhibition of 5-HT release as well
as 5-HT receptor desensitization; both may also contribute to the
transient effect of d-fenﬂuramine on GSK3 phosphorylation.
The inhibitory control of GSK3 by 5-HT is further demon-
strated by an elegant study (Beaulieu et al., 2008b) in a
mouse model where mice carry a mutation in the tryptophan
hydroxylase-2 (TPH-2) gene that is equivalent to a rare human
variant (R441H) identiﬁed in a few individuals with major depres-
sive disorder (Zhang et al., 2005). The homozygous mutant mice,
when compared to littermate wild type mice, have signiﬁcantly
lower levels of the 5-HTprecursor 5-hydroxytryptophan (5-HTP),
5-HT, and its metabolite 5-Hydroxyindoleacetic acid (5-HIAA)
in the frontal cortex, hippocampus, and striatum. Meanwhile,
the level of phosphorylated serine-9 of GSK3β is signiﬁcantly
lower, and GSK3 activity is elevated in the same brain regions
of the mutant mice (Beaulieu et al., 2008b). Therefore, a sus-
tained deﬁciency of 5-HT may reset the activity level of GSK3
in brain to higher level, compared to wild type mice where
the constitutively active GSK3 is likely under inhibitory regula-
tion (Doble and Woodgett, 2003). The overactive GSK3 in the
R441H mutant mice may be involved in the behavioral abnor-
malities of these mice, since the depressive- and anxiogenic-
like behavioral phenotypes of these mice were largely reversed
by a GSK3 inhibitor, and by genetically reducing the level of
GSK3β.
BEHAVIORAL SIGNIFICANCE OF GSK3 REGULATION BY 5-HT
Regulation of GSK3 by 5-HT may have functional signiﬁcance
in maintaining brain physiology and behaviors that are regulated
by serotonergic neurotransmission. The 5-HT reuptake inhibitor
antidepressant ﬂuoxetine has been shown to increase phospho-
Ser9-GSK3β in the cerebral cortex, hippocampus, striatum, and
cerebellum of mouse brain (Li et al., 2004, 2007; Beaulieu et al.,
2008b) and phospho-Ser21-GSK3α in the hippocampus (Polter
et al., 2011). Several studies also suggest that inhibition of GSK3β
is an important intermediate step in the antidepressant effect of
ﬂuoxetine. In the TPH-2 mutant mice, abnormal behavior asso-
ciated with 5-HT deﬁciency is mediated by GSK3β (Beaulieu
et al., 2008b). Additionally, inhibition of GSK3 by small mole-
cule inhibitors or in GSK3β-deﬁcient mice have been shown to
reduce immobility in the forced swim test (Gould et al., 2004;
Kaidanovich-Beilin et al., 2004; O’Brien et al., 2004; Beaulieu et al.,
2008a; Rosa et al., 2008), similarly to the antidepressants ﬂuoxetine
(Page et al., 1999; Bianchi et al., 2002). We have recently tested this
behavioral effect of ﬂuoxetine inmutant GSK3 knock-in (KI)mice
in which serine-9 of GSK3β or serine-21 of GSK3αwas substituted
with alanine (S9A-GSK3β-KI and S21A-GSK3α-KI; McManus
et al., 2005; Polter et al., 2010). These mice have normal levels of
GSK3β and GSK3α, but the N-terminal serine cannot be regulated
by phosphorylation. In the forced swim test (Porsolt et al., 1977)
the baseline immobility (saline treatment) was not signiﬁcantly
different between S9A-GSK3β-KI,S21A-GSK3α-KI, and littermate
wild type mice. As expected, wild type mice responded to ﬂuox-
etine (20mg/kg, i.p., 30min) with a signiﬁcant 56% reduction in
immobility when compared to saline-treated mice. However, the
anti-immobility effect of ﬂuoxetine in S9A-GSK3β-KI mice was
markedly diminished, with only 17% non-signiﬁcant reduction
of immobility (Polter et al., 2011). Although ﬂuoxetine was able
to increase phospho-Ser21-GSK3α in the hippocampus, S21A-
GSK3α-KI mice partially responded to ﬂuoxetine in the forced
swim test. Therefore, phosphorylation of GSK3β predominantly
mediates the acute antidepressant-like effect of ﬂuoxetine, which
reinforces the importance of phosphorylation of GSK3β in the
therapeutic action of ﬂuoxetine (Figure 1).
Since the antidepressant effect of ﬂuoxetine in human only
appears after chronic administration, to associate GSK3 regu-
lation by ﬂuoxetine to a therapeutic effect, it is important to
determine if chronic ﬂuoxetine treatment also regulates GSK3β.
This has recently be reported by Okamoto et al. (2010) who
found that chronic ﬂuoxetine administration for 3weeks sig-
niﬁcantly increased phospho-Ser9-GSK3β in mouse hippocam-
pus. Although this is the only selective 5-HT reuptake inhibitor
thus far shown to increase phospho-Ser9-GSK3β upon chronic
treatment, a dual-acting antidepressant venlafaxine (blocks both
5-HT and norepinephrine transporters) has also been shown
to increase phospho-Ser9-GSK3β after chronic administration
(Okamoto et al., 2010). When investigating the effect of chronic
treatment with imipramine, a TCA that inhibits reuptake of both
5-HT and norepinephrine on activation of Akt and down-stream
transcription factor FoxO3a (Polter et al., 2009), we also noticed
a signiﬁcant increase in the level of phospho-Ser9-GSK3β in the
cerebral cortex, hippocampus, and striatum of mouse brain after
4 weeks of intraperitoneal administration (Figure 2). It is not yet
veriﬁed if the effect of venlafaxine and imipramine on GSK3β is a
combined action via both 5-HT and norepinephrine, as regulation
of brain GSK3β by selective adrenergic-enhancing drugs has not
been studied.
REGULATION OF GSK3 BY 5-HT1A RECEPTORS
ACTIVATION OF 5-HT1A RECEPTORS REGULATES GSK3 BY
PHOSPHORYLATION
Withmanyphysiological actions of brain 5-HT that are divergently
mediated by 5-HT receptor subtypes, it is critically important to
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FIGURE 1 | Schematic illustration of GSK3 as an intermediate
modulator of 5-HT receptor-mediated signaling pathways and
physiological functions. AAP, atypical antipsychotic; α, β, γ, G-protein
subunits; AC, adenylyl cyclase; AD, antidepressant; β-arr, β-arrestin; DG,
diacylglycerol; Gi/Gq, G-protein; GSK3, glycogen synthase kinase-3; 5HT,
serotonin; 5-HT1A and 5-HT2A, serotonin receptor subtypes; P,
phosphorylated; PDK1, phosphoinositide-dependent kinase-1; PI3K,
phosphatidylinositol-3-kinase; PP1/PP2A: protein phosphatase 2A; PKA,
protein kinase A; PKC, protein kinase C. TS, tail suspension; FS, forced
swim; DLE, dark-light emergence; SI, social interaction; FC, fear
conditioning.
determine the receptor subtypes that transduce 5-HT signal to
inhibition of GSK3. In mice treated with d-fenﬂuramine, the 5-
HT1A receptor antagonistWAY100635 was able to block over 60%
of d-fenﬂuramine-induced increase in phospho-Ser9-GSK3β, sug-
gesting that 5-HT1A receptors have a major role in mediating
the GSK3-regulating effect of 5-HT. Indeed, when mice receive
a single systemic administration of 5-HT1A receptor agonist 8-
hydroxy-N,N -dipropyl-2-aminotetralin (8-OH-DPAT), the level
of phospho-Ser9-GSK3β, but not total GSK3β, is signiﬁcantly
increased in the cerebral cortex, hippocampus, and striatum (Li
et al., 2004). 8-OH-DPAT is also able to increase the level of
phospho-Ser21-GSK3α in the hippocampus, but the effect is less
robust (Polter et al., 2011).
In the hippocampus, a brain area that is enriched in 5-HT1A
receptors (Hoyer et al., 2002), GSK3β is ubiquitously expressed
with high level of immunoreactivity in neuronal cell bodies and
dendritic processes (Peineau et al., 2007; Perez-Costas et al., 2010).
8-OH-DPAT-induced increase in phospho-Ser9-GSK3β is partic-
ularly prominent in the dendrites and cell bodies of CA3, and is
observable in the cell bodies and projections of dentate granule
cells and the dendrites of CA1 (Polter et al., 2011). The quantiﬁed
ratio of phospho-Ser9-GSK3β to nuclearmarker in the subﬁelds of
the hippocampus reveals signiﬁcant increases in the stratum pyra-
midale and the stratum radiatum/stratum lucidum of CA3 and in
the hilus of the dentate gyrus. Therefore, the response of GSK3β
FIGURE 2 | Regulation of phospho-Ser-GSK3 by chronic imipramine
treatment in mouse brain. C57BL/6 mice were treated with imipramine
(20mg/kg/d, i.p.) for 28 days before brain dissection. Homogenates of the
cerebral cortex (CTX), hippocampus (HIP), and striatum (STR) were
immunoblotted for phospho-Ser21-GSK3α, phospho-Ser9-GSK3β, total
GSK3α and total GSK3β, and data are quantiﬁed by densitometry. Protein
levels in imipramine-treated samples are calculated as percentage control
(saline treatment). Data are mean±SEM. *p<0.05 (n =7–9 per group)
when values are compared to saline treatment in Student’s t -test.
to systemic administration of 8-OH-DPAT in the hippocampus
is preferentially in the pyramidal glutamatergic neurons and their
dendrites, suggesting that regulation of GSK3β by 5-HT1A recep-
tors may have functional impact on the glutamatergic circuits
of the hippocampus. GSK3β has been shown to be a mediator
of glutamate receptor activity and synaptic plasticity in the hip-
pocampus (Hooper et al., 2007; Peineau et al., 2007; Du et al.,
2010), thus regulation of GSK3β by 5-HT1A receptors in the hip-
pocampus may further link this 5-HT signaling mechanism to
hippocampal regulation of learning and memory.
THE ROLE OF GSK3 IN 5-HT1A RECEPTOR-REGULATED BEHAVIORS AND
OTHER PHYSIOLOGICAL FUNCTIONS
Among 5-HT1A receptor-regulated behaviors, inhibition of con-
textual fear conditioning, a form of associative learning (Kim and
Jung, 2006), is a hippocampus-dependent function (Stiedl et al.,
2000; Tsetsenis et al., 2007; Ogren et al., 2008). To determine the
role of GSK3β in 5-HT1A receptor-regulated fear conditioning,
we tested the expression of contextual and cued fear responses in
S9A-GSK3β-KI, S21A-GSK3α-KI, and littermate wild type mice.
In wild type mice, 8-OH-DPAT (1mg/kg, i.p.) injected 30min
prior to contextual test completely suppressed a standard fear
conditioning training-induced contextual freezing (Polter et al.,
2011). Compared to wild type mice, S9A-GSK3β-KI mice also
exhibited increased freezing in contextual tests, but 8-OH-DPAT
had no signiﬁcant effect in reducing the context freezing. In con-
trast to S9A-GSK3β-KI mice, S21A-GSK3α-KI mice responded to
8-OH-DPAT in contextual freezing similarly as wild type mice.
Thus, inhibition of GSK3β, but not GSK3α, via 5-HT1A receptors
is a necessary intermediate process for 5-HT1A receptor-regulated
inhibition of contextual fear learning. This function of GSK3β is
Frontiers in Molecular Neuroscience www.frontiersin.org October 2011 | Volume 4 | Article 31 | 4
Polter and Li Serotonin and GSK3
selective to the contextual content since the response of cued fear
learning to 8-OH-DPAT was similar in S9A-GSK3β-KI mice and
wild type mice.
The functional signiﬁcance of GSK3β in 5-HT1A receptor-
mediated physiological functions is not limited to contextual fear
learning. In cultured rat hippocampal neurons, 5-HT1A recep-
tor activation by 8-OH-DPAT increases phospho-Ser9-GSK3β
and stimulates mitochondrial movements in the axons, an effect
mimicked by a GSK3 inhibitor (Chen et al., 2007). This ﬁnding
suggests the importance of GSK3β in 5-HT1A receptor-mediated
regulation of energy distribution in neurons. In Drosophila, over-
expressing the mammalian 5-HT1A receptor ortholog d5-HT1B
receptor increases the level of phosphorylated serine of SHAGGY
(SGG), the Drosophila GSK3β (Yuan et al., 2005). This inhibitory
regulation of SGG by d5-HT1B receptor prevents SGG from phos-
phorylating timeless (TIM) protein for light-induced degradation.
Therefore, d5-HT1B receptor reduces behavioral phase shifts in
Drosophila by increasing phospho-Ser-SGG. The role of GSK3 in
other 5-HT1A receptor-mediated functions remains to be elu-
cidated, but this could be an exciting area in therapeutic drug
development, as GSK3 inhibitors, when applied appropriately,
may rescue abnormal physiology and behaviors due to functional
deﬁciency of 5-HT1A receptors in brain.
SIGNALING MECHANISMS MEDIATING THE EFFECT OF 5-HT1A
RECEPTORS ON GSK3
5-HT1A receptors activate Gi-coupled signal pathways. In a recent
study, Talbot et al. (2010) found that mice expressing regulators
of G protein signaling (RGS)-insensitive Giα2 have increased sen-
sitivity to 8-OH-DPAT-induced activation, and exhibit elevated
levels of cortical and hippocampal phospho-Ser9-GSK3β. This
effect of RGS-insensitive active Giα2 was blocked by the 5-HT1A
receptor antagonist WAY100635. This ﬁnding suggests that regu-
lation of GSK3β by 5-HT1A receptors is mediated by a Gi-coupled
signaling pathway (Figure 1). However, activation of Giα2 results
in inhibition of adenylyl cyclase and inactivation of PKA.Although
PKA is one of the several protein kinases that phosphorylate
GSK3β on the serine-9 residue (Fang et al., 2000; Li et al., 2000), it
is unlikely that this conventional Giα-coupled signaling pathway
is responsible for direct phosphorylation of GSK3β. Alternatively,
5-HT1A receptor agonists have consistently shown to increase Akt
phosphorylation in neuronal cells, including hippocampal derived
HN2-5 cells (Adayev et al., 1999), primary hippocampal neu-
rons (Cowen et al., 2005; Chen et al., 2007), and primary fetal
rhombencephalic neurons (Druse et al., 2005). Regulation of Akt
by 5-HT1A receptors is mediated by phosphoinositide 3-kinase
(PI3K; Cowen et al., 2005; Hsiung et al., 2005, 2008), and is sensi-
tive to inhibition of Giα activity by pertussis toxin (Cowen et al.,
2005). Furthermore, activation of Akt by 5-HT1A receptors can
be inhibited by cAMP and restored after inactivation of PKA (Hsi-
ung et al., 2008). Therefore, 5-HT1A receptor-induced activation
of Akt likely follows 5-HT1A receptor-induced activation of the
Giα–adenylyl cyclase–cAMP–PKA signaling pathway. Since Akt is
another major protein kinase that regulates phospho-Ser9-GSK3β
(Cross et al., 1995), Akt may mediate 5-HT1A receptor-induced
GSK3β phosphorylation. Indeed, systemic treatment of mice with
the 5-HT1A receptor agonist 8-OH-DPAT signiﬁcantly increased
the active phospho-Thr308-Akt in the hippocampus, and intra-
hippocampal infusion of the PI3K inhibitor LY294002 blocked
both phospho-Thr308-Akt and phospho-Ser9-GSK3β in response
to 8-OH-DPAT (Polter et al., 2011).
SELECTIVITY OF GSK3 REGULATION BY 5-HT1A RECEPTORS
As discussed above, activation of 5-HT1A receptors increases
both phospho-Ser9-GSK3β and phospho-Ser21-GSK3α in the
hippocampus, however, the magnitude of response in GSK3α is
smaller than GSK3β (Polter et al., 2011). Additionally, regulation
of GSK3αphosphorylation by 5-HT1A receptors has less impact in
fear conditioning (Polter et al., 2011). These pilot studies suggest
different roles of GSK3 isoforms in mediating the physiological
and behavioral functions of 5-HT1A receptors. Additional studies
are needed to differentiate the response of GSK3α andGSK3β to 5-
HT1A receptor agonists in different brain regions, and to compare
the impact of each GSK3 isoform in other 5-HT1A receptor-
regulated behaviors, which may provide valuable information on
thephysiological andbehavioral impacts of the twoGSK3 isoforms
in 5-HT neurotransmission.
A caveat of studying 5-HT1A receptor-regulated signaling in
brain is that the differential functions of 5-HT1A autoreceptors
and heteroreceptors in different brain regions have divergent func-
tions. Thus, systemic treatment of animals with 5-HT1A receptor
agonists can activate 5-HT1A autoreceptors to reduce ﬁring of
raphe 5-HT neurons projected to other brain regions, but simul-
taneously activate 5-HT1A heteroreceptors in those brain regions,
such as the hippocampus. Therefore, the effect seen after global
activation of 5-HT1A receptors may involve indirect response
of GSK3 to activation or inhibition of other neurotransmitters.
Therefore, additional studies of GSK3 regulation by systemically
and regionally applied 5-HT1A receptor agonists in speciﬁc neu-
ron populations in combination with studies in isolated primary
neuron cultures will further elucidate the sophisticated mecha-
nisms underlying theGSK3-regulating effect of 5-HT1A receptors.
Nevertheless, the effect of global activation of 5-HT1A receptors
should be appreciated since systemic drug treatment is likely more
relevant to therapeutic implications.
REGULATION OF GSK3 BY 5-HT2A RECEPTORS
THE PARADOXICAL EFFECTS OF 5-HT2A RECEPTOR AGONISTS AND
ANTAGONISTS ON GSK3
Although 5-HT1A receptors have a prominent regulatory effect
on GSK3, more than one 5-HT receptor subtype should be acti-
vated upon elevated brain 5-HT. Among them, 5-HT2A recep-
tors have been found to regulate GSK3 with rather sophisticated
and yet unidentiﬁed mechanisms. We previously reported that
activation of 5-HT2A receptors by systemic administration of 1-
(2,5-dimethoxy-4-iodophenyl)-propan-2-amine (DOI) for 1 h (a
time point that maximally increases phospho-Ser9-GSK3β by d-
fenﬂuramine, ﬂuoxetine, and 8-OH-DPAT), had little effect on
phospho-Ser9-GSK3β in the cerebral cortex, hippocampus, or
striatum (Li et al., 2004). However, Abbas et al. (2009) later
reported that a brief 15-min DOI treatment caused an increase
in phospho-Ser9-GSK3β in the mouse brain, although this report
did not specify the brain region in which this effect was seen. If the
time length of treatment is the major difference of the discrepant
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ﬁndings, one possibility is that 1 h treatment might have caused
desensitization of 5-HT2A receptors. Therefore a thorough kinetic
study of 5-HT2A receptor agonists may further clarify their effect
on GSK3, especially the effects in different brain regions.
Since activation of 5-HT2A receptors by the hallucinogen DOI
is somewhat different from 5-HT-induced activation of 5-HT2A
receptors (Schmid et al., 2008), the exact action of 5-HT2A recep-
tor activation on GSK3 phosphorylation should be further eluci-
dated using endogenous 5-HT2A receptor agonists and selective
5-HT2A receptor antagonists. However, this has been difﬁcult
to study with 5-HT2A receptors, because it is already known
that endogenous 5-HT increases phospho-Ser-GSK3 by activat-
ing other 5-HT receptors, particularly 5-HT1A receptors (Li et al.,
2004); whereas selective blocking 5-HT2A receptors with their
antagonists, one of the commonly used manipulations to deter-
mine a receptor-selective effect, paradoxically elicit robust increase
in the level of phospho-Ser-GSK3 in mouse brain. This phenom-
enon was ﬁrst observed with the non-selective 5-HT2 receptor
antagonist LY53857 (Li et al., 2004). Systemic LY53857 treat-
ment not only caused a prolonged elevation of phospho-Ser9-
GSK3β, but it also potentiated the GSK3β-regulating effect of d-
fenﬂuramine and 8-OH-DPAT. This effect has also been observed
using the 5-HT2A receptor-selective antagonistMDL11939,which
elevates both phospho-Ser21-GSK3α and phospho-Ser9-GSK3β
in mouse brain, with the effect more prominent in the cerebral
cortex and striatum and less in the hippocampus (Figure 3A).
THE EFFECT OF ATYPICAL ANTIPSYCHOTICS ON GSK3
Despite the paradoxical nature of 5-HT2A receptors in regulat-
ing GSK3, the effect of 5-HT2A receptor antagonists may have
clinical signiﬁcance. Several independent studies have found that
antipsychotic drugs, including both conventional and atypical
antipsychotics, regulate GSK3 in animal brain. The conventional
antipsychotic haloperidolwas reported to either alter thephospho-
rylation state or increase the protein level of GSK3 (Alimohamad
et al., 2005; Kozlovsky et al., 2006; Roh et al., 2007). A group of
atypical antipsychotics, including risperidone, olanzapine, cloza-
pine, quetiapine, and ziprasidone, were consistently found to
increase phospho-Ser-GSK3 in mouse brain (Alimohamad et al.,
2005; Li et al., 2007; Roh et al., 2007). Although the dopamine D2
receptor-blocking property of these agentsmaybe involved in their
GSK3-regulating effect (Beaulieu et al., 2009), one of the major
pharmacological difference between conventional antipsychotics
and atypical antipsychotics is that the latter group has a dual
antagonistic action on both 5-HT2 receptors and dopamine D2
receptors (Schotte et al., 1995). In our study, a low dose haloperi-
dol that binds to D2 receptors but not 5-HT2A receptors had no
effect on mouse brain GSK3 (Li et al., 2007). In contrast, systemic
administered risperidone increases brain phospho-Ser9-GSK3β at
a dose as low as 0.1mg/kg (Li et al., 2007). As the average dose of
risperidoneused to attain a 50% in vivo blockadeof D2 receptors in
rats is about 0.3mg/kg (Kapur et al., 2003), and the binding afﬁnity
of risperidone to 5-HT2A receptors is at least 3 times higher than
to D2 receptors (Weiner et al., 2001), it is likely that the increase of
phospho-Ser9-GSK3β by the low dose risperidone involves block-
ing 5-HT2A receptors. It remains to be determined if putative
5-HT2A receptor antagonists have similar clinical implications
FIGURE 3 | Regulation of phospho-Ser-GSK3 by 5-HT2A receptor
ligands in mouse brain. (A)Wild type mice were treated with saline (Veh)
or the 5-HT2A receptor antagonist MDL11939 (MDL, 4mg/kg, i.p., 1 h).
Immunoblots of phospho-Ser21-GSK3α, phospho-Ser9-GSK3β, total GSK3α,
and total GSK3β in the cerebral cortex, hippocampus, and striatum are
quantiﬁed by densitometry. Mean±SEM, *p<0.05 when values are
compared to saline treatment in Student’s t -test, n =4–13. (B)Wild type
(WT) and β-arrestin2-knockout (KO) mice were treated with saline (Veh) or
DOI (20mg/kg, i.p.) for 1 h. Immunoblots of phospho-Ser21-GSK3α,
phospho-Ser9-GSK3β, total GSK3α, and total GSK3β in the cerebral cortex,
hippocampus, and striatum are quantiﬁed by densitometry. Mean±SEM,
*p<0.05 between saline and DOI treatment within the same genotype,
Student’s t -test; **p<0.05, two-way ANOVA followed by Holm–Sidak
comparison, n =10–12.
as atypical antipsychotics, and if such effects are dependent on
regulation of GSK3.
Clinically, atypical antipsychotics have indications in both
psychotic disorders and mood disorders (Derry and Moore,
2007; Philip et al., 2008). Some atypical antipsychotics, either as
monotherapy or augmentation, have shown efﬁcacy in ameliorat-
ing symptoms of depression (Tohen et al., 2003; Calabrese et al.,
2005; Berman et al., 2007; Marcus et al., 2008; Bauer et al., 2009).
Interestingly, a combination treatmentwith risperidone andﬂuox-
etine enhance the effect of either agent alone on phosphorylation
of GSK3β in the rodent brain (Li et al., 2007). This effect agrees
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with the ﬁnding that the 5-HT2 receptor antagonist LY53857
potentiated the effect of d-fenﬂuramine and8-OH-DPATonGSK3
phosphorylation. However, the role of GSK3 in this clinically rel-
evant combination effect between antidepressants and atypical
antipsychotics remains to be determined.
SIGNALING MECHANISMS INVOLVED IN REGULATION OF GSK3 BY
5-HT2A RECEPTORS
Few studies have investigated the signalingmechanisms thatmedi-
ate the effects of either 5-HT2A receptor agonists or antagonists
on GSK3 phosphorylation. Classically, the 5-HT2A receptors cou-
ple to Gq protein that activates PLC and its down-stream PKC
(Carr et al., 2002; Figure 1). PKC was reported to mediate DOI-
induced Erk phosphorylation in the brain (Schmid et al., 2008).
Since PKC is one of the protein kinases that regulate GSK3 phos-
phorylation (Goode et al., 1992), it would be straightforward if
the PLC/PKC signaling mechanism is found to mediate 5-HT2A
receptor-regulated GSK3. However, this mechanism has not been
reported, especially since the kinetic correlation between 5-HT2A
receptor activation and phosphorylation of GSK3 has not been
characterized. In a study of dopamine D2 receptor-regulated sig-
naling (Beaulieu et al., 2004), the intracellular scaffolding protein
β-arrestins were found to negatively affect GSK3 phosphorylation
in mouse brain, wherein activation of dopamine D2 receptors
reduces phospho-Ser9-GSK3 due to inactivation of Akt by pro-
tein phosphatase-2 (PP2A) in a β-arrestin2-driven protein com-
plex (Beaulieu et al., 2005). D2 receptor antagonists block this
effect of dopamine and increase phospho-Ser-GSK3 by disrupting
the effect of β-arrestins. 5-HT2A receptors also interact with β-
arrestins in a cell type- and ligand-selective manner (Gelber et al.,
1999; Allen et al., 2008; Schmid et al., 2008; Schmid and Bohn,
2010), but the role of β-arrestins in 5-HT2A receptor-regulated
signal pathways is less understood. It should be noted that in a
previous study by Schmid et al. (2008), DOI-induced head twitch,
receptor internalization, and Erk phosphorylation are not depen-
dent on the presence or absence of β-arrestins. However, we have
recently found that DOI treatment for 1 h induced a signiﬁcant
over twofold increase in phospho-Ser21-GSK3α and phospho-
Ser9-GSK3β in the cerebral cortex, hippocampus, and striatum
in β-arrestin2-knockout mice, an effect that is not seen in wild
type mice (Figure 3B). This observation suggests that β-arrestin2
may inﬂuence how 5-HT2A receptors regulate GSK3. Future
studies investigating signal transduction mechanisms mediating
the effect of 5-HT2A receptors on GSK3 should include not
only PLC/PKC signaling, but also β-arrestin-mediated signaling.
Additionally, since 5-HT2A receptors are involved in modulating
dopamine neurotransmission (Alex and Pehek, 2007; Di Giovanni
et al., 2008; Esposito et al., 2008), a potential indirect effect of 5-
HT2A receptors on D2 receptor-regulated GSK3 should also be
considered.
GSK3 SELECTIVELY REGULATES 5-HT1B
RECEPTOR-MEDIATED SIGNAL TRANSDUCTION AND
FUNCTION
Glycogen synthase kinase-3 phosphorylates many protein sub-
strates that distribute in both neural and peripheral tissues (Wood-
gett, 2001; Jope and Johnson, 2004). As a result, in vivo inhibition
of GSK3 can have a variety of physiological effects. Thus, identify-
ing GSK3 substrates that have speciﬁc functions in brain circuits
could be critical in developing GSK3-targeting treatment for ther-
apeutics.With each clearly identiﬁed substrate, substrate-targeting
inhibition of brain GSK3 activity may lead to selective modulation
of physiological function of the brain. Most 5-HT receptor sub-
types, except 5-HT3 receptors, are G-protein coupled receptors
(GPCRs) that represent the largest group of drug targets. Besides
activation by receptor ligands, the activity of GPCRs can be modu-
lated by posttranslational modiﬁcations, such as phosphorylation
by protein kinases (Tobin, 2008), or interaction with intracellular
proteins (Ritter and Hall, 2009; Bockaert et al., 2010). However,
little evidence has shown GPCR regulation by GSK3.
DIRECT INTERACTION BETWEEN GSK3β AND 5-HT1B RECEPTORS
In an effort to identify GSK3 substrates within the 5-HT neu-
rotransmission system, we searched GSK3 consensus phosphory-
lation sequence for primed substrates – pre-phosphorylated by
a serine/threonine kinase to allow access of GSK3 to the ser-
ine/threonine located four amino acids N-terminal of the primed
site (Doble and Woodgett, 2003). Somewhat surprisingly, both
human and mouse 5-HT1B receptors were found to contain eight
GSK3 consensus phosphorylation sites spreading within intracel-
lular loops 1, 2, and 3 of the receptor. In contrast, the highly
homologous 5-HT1A receptors have no GSK3 consensus sites
in intracellular loops 1 and 2, and the two sites in intracellular
loop-3 of human 5-HT1A receptors are not homologous with
mouse 5-HT1A receptors. In cultured heterologous cells express-
ing 5-HT1B or 5-HT1A receptors, GSK3β was found to directly
associate with 5-HT1B receptors (Chen et al., 2009), which was
detected using the bioluminescence resonance energy transfer
(BRET) assay that measures the proximity of two proteins within
a distance of 1–10 nm (Angers et al., 2000), and conﬁrmed by co-
immunoprecipitation of 5-HT1B receptors and GSK3β. Intrigu-
ingly, this interaction of GSK3β is selective to 5-HT1B receptors,
as GSK3β does not interact with 5-HT1A receptors (Chen et al.,
2009). Mutation of every potential GSK3 consensus phosphoryla-
tion site of 5-HT1B receptors by replacing the serine with alanine
further shows that GSK3β associates with 5-HT1B receptors at the
[pS(154)AKRpT(158)] sequence located in the i2-loop of 5-HT1B
receptors (Chen et al., 2009).
GSK3β DIFFERENTIALLY INFLUENCES 5-HT1B RECEPTOR ACTIVITY AND
ASSOCIATED SIGNALINGS
Both 5-HT1B and 5-HT1A receptors couple to Gi-protein, activa-
tion of which causes inhibition of adenylyl cyclase and reduction
of cAMP. Disrupting the interaction between 5-HT1B receptors
and GSK3β by mutating the GSK3β-interactive Ser-154 residue
of the receptor (S154A–5-HT1B receptor) effectively abolishes
5-HT-induced conformational change between 5-HT1B recep-
tors and Giα2 (Chen et al., 2011). In accordance with altered
activity of Giα2, GSK3β-insensitive S154A–5-HT1B receptor does
not respond to 5-HT in assay of 5-HT-induced inhibition of
cAMP (Chen et al., 2009). These data highly suggest that GSK3β
has a functional impact on 5-HT1B receptor-mediated signaling.
Indeed, several small molecule GSK3 inhibitors and the clinically
used lithium are able to disrupt 5-HT-induced conformational
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change between 5-HT1B receptors and Giα2 and inhibition of
cAMP. This is a highly selective function of the GSK3β isoform, as
it only occurs in cells with GSK3β-knockdown or over-expressing
inactive GSK3β, but GSK3α-knockdown does not affect 5-HT1B
receptor-associated Giα–cAMP signaling (Chen et al., 2009, 2011).
This is another example showing that despite GSK3α and GSK3β
are highly homologous and are regulated via similar upstream
mechanisms, the two isoforms of GSK3 have different substrates
and mediate different physiological functions (Wang et al., 1994;
Liang and Chuang, 2006). In agreement with a selective inter-
action between GSK3β and 5-HT1B receptors, GSK3 inhibitors
and molecular manipulation of intracellular GSK3β do not alter
5-HT-induced 5-HT1A receptor-Giα2 interaction or 5-HT1A
receptor-mediated inhibition of cAMP.
Giα-mediated cAMP production is not the only GSK3-
dependent signaling pathway of 5-HT1B receptors as activation
of Akt by 5-HT or the selective 5-HT1B receptor agonist anpirto-
line is also signiﬁcantly diminished in the mutant S154A–5-HT1B
receptor-expressing cells (Chen et al., 2011). The mechanisms of
regulating Akt by 5-HT1B receptors are not fully understood, but
since both α- and βγ-subunits of G-proteins may be linked to
GPCR-induced activation of Akt (DeWire et al., 2007; New et al.,
2007; Yang et al., 2009), the effect of GSK3β on 5-HT1B receptor-
induced Akt activation could be a consequence of the promi-
nent effect of GSK3β on 5-HT1B receptor-associated Gi-protein.
In addition, since Akt is one of the upstream GSK3-regulating
protein kinases that inactivates GSK3 (Cross et al., 1995), the
GSK3-dependent activation of Akt by 5-HT1B receptors could
function as a feedback regulation to prevent prolonged effect of
GSK3β on 5-HT1B receptors, but this postulation remains to be
examined.
As a GPCR, 5-HT1B receptors are expected to interact with β-
arrestins that have been recognized to interact with many GPCRs
and play important roles in GPCR internalization and alterna-
tive signaling (Lefkowitz and Shenoy, 2005). Indeed, we found
that β-arrestin2 can be recruited to 5-HT1B receptors in response
to 5-HT. However, in contrast to the prominent effect of GSK3β
on 5-HT1B receptor-coupling to Giα2, removing, or inhibiting
GSK3β did not affect β-arrestin2 recruitment to 5-HT1B recep-
tors (Chen et al., 2011). As a chaperone protein, recruitment of
β-arrestins to GPCRs initiates receptor internalization and desen-
sitization (Bohn et al., 1999, 2000). 5-HT was able to internalize
both wild type and S154A–5-HT1B receptors in 5-HT1B receptor-
expressing cells (Chen et al., 2009). If this internalization event is
directed by β-arrestin2, it is in agreement with our ﬁnding that
β-arrestin2 recruitment to 5-HT1B receptors is independent of
GSK3β. However, the time course of 5-HT1B receptor internal-
ization is drastically different between wild type and the mutant
S154A–5-HT1B receptors, wherein wild type receptors rapidly
reappear on the cell membranes within 60min of 5-HT treatment,
while mutant GSK3β-insensitive receptors continue to be absent
from the cell surface 2 h after 5-HT treatment. This suggests a
potentially important function of GSK3β in an unidentiﬁedmech-
anism that is crucial for 5-HT1B receptor synthesis andmembrane
recycling.
Interestingly, the effect of GSK3β on 5-HT1B receptors appears
to facilitate activity and functional recovery, which is opposite
from other GPCR-regulating protein kinases (GRKs) that typi-
cally facilitate desensitization and termination of GPCR activity
(Gainetdinov et al., 2004). The underlying importance of GSK3β
on 5-HT1B receptor-mediated Gi signaling and β-arrestin recruit-
ment is thatGSK3βdoesnot function as a general 5-HT1B receptor
activator, instead, GSK3β selectively modulates signaling-speciﬁc
actions of 5-HT1B receptors. This effect of GSK3β could be attrac-
tive when developing GSK3-targeting therapeutic agents, as inhi-
bition of GSK3β would not make inert 5-HT1B receptors, but
to selectively shift 5-HT1B receptor-mediated physiological and
behavioral functions toward aGi signaling-independent direction.
This postulation is an important area of future research especially
when β-arrestin-associated 5-HT1B receptor signaling pathways
are identiﬁed.
EFFECT OF GSK3 INHIBITORS ON THE PHYSIOLOGICAL FUNCTIONS OF
5-HT1B RECEPTORS
Noticeably, several earlier studies showed that lithium selectively
inhibits 5-HT binding to 5-HT1B receptors, reduces 5-HT1B
receptor-inducedGTPγs binding, and abolishes 5-HT1B receptor-
reduced adenylyl cyclase activity (Massot et al., 1999). Similar
results have been observed in human platelets from both healthy
and depressed subjects where lithium dose-dependently reverses
the inhibitory effect of a 5-HT1BR agonist on adenylyl cyclase
(Januel et al., 2002). In animal behavior studies, lithium selec-
tively regulates the behavioral effect of 5-HT1B receptor agonists,
but not the effect of 5-HT1A receptor agonists (Redrobe and
Bourin, 1999). With lithium being a selective GSK3 inhibitor
(Klein and Melton, 1996), it is highly likely that the selective effect
of lithium on 5-HT1B receptor function is the result of its inhi-
bition of GSK3. Since lithium is a therapeutic drug that has been
found to inhibit GSK3 in vivo, perhaps by both its direct and
indirect actions on GSK3 (Klein and Melton, 1996; Chalecka-
Franaszek and Chuang, 1999; De Sarno et al., 2002), disrupt-
ing the interaction between 5-HT1B receptors and GSK3β may
have signiﬁcant impact in the physiological functions of 5-HT1B
receptors and relevant therapeutic effects in neuropsychiatric
diseases.
The above postulation has been tested now in mouse brain tis-
sues using small GSK3 inhibitors. When mouse cerebral cortical
slices are pre-treated with the GSK3 inhibitors 6-bromoindirubin-
3′-oxime (BIO) or kenpaullone, both inhibitors concentration-
dependently abolish the inhibitory effect of 5-HT1B receptor
agonist anpirtoline on forskolin-stimulated cAMP, whereas nei-
ther affects the effect of 5-HT1A receptor agonist 8-OH-DPAT on
cAMP (Chen et al., 2009). This ﬁnding in brain tissues is consis-
tent with ﬁndings in cultured cells, where ablation or inhibition
of GSK3β selectively abolishes 5-HT1B receptor-mediated Giα–
cAMPsignaling. Furthermore,pre-treatment of cortical sliceswith
the GSK3 inhibitors AR-A014418 (Bhat et al., 2003) and BIP-135
(Gaisina et al., 2009) completely abolish the inhibitory effect of
anpirtoline on potassium-evoked 3H-5-HT release (Chen et al.,
2011). Since negatively regulating 5-HT release is a characteris-
tic function of 5-HT1B autoreceptors in the axon terminals of
5-HT neurons (Trillat et al., 1997; Riad et al., 2000; Sari, 2004),
this ﬁnding suggests that active GSK3 plays a role to rapidly resets
the surge of 5-HT to baseline, which may result in termination
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of a physiological or behavioral action of 5-HT. In reverse, inhi-
bition of GSK3 may be important in maintaining 5-HT at a
sufﬁcient level that allows 5-HT to deliver sustained physiological
action. The signaling pathways mediating 5-HT1B autoreceptor-
induced inhibition of 5-HT release have never been conﬁrmed. In
a study conducted in 5-HT1B receptor-expressing cardiac ventri-
cle myocytes, inhibition of 5-HT release by 5-HT1B receptors was
found to be a pertussis toxin-sensitive Gi-mediated effect, where
the effect was not mediated by cAMP, but by an inwardly rectify-
ing potassium channel (Ghavami et al., 1997). However, pertussis
toxin-dependent 5-HT release by 5-HT1B receptors in the brain
has not been conﬁrmed. It should therefore be noted that although
GSK3 inhibitors abolish the effect of 5-HT1B receptors on Gi-
associated signalings and 5-HT release, the latter is not necessarily
due to the impaired 5-HT1B receptor-Giα coupling.
EFFECT OF GSK3 INHIBITORS ON 5-HT1B RECEPTOR-REGULATED
BEHAVIORS
If GSK3β differentially affects 5-HT1B receptor-mediated sig-
nal transduction and brain physiological function, it would
be expected that GSK3 inhibitors may also differentially
affect 5-HT1B receptor-regulated behaviors. Indeed, intra-
cerebroventricular infusion of GSK3 inhibitor AR-A014418 or
BIP-135 prior to systemic administration of anpirtoline signiﬁ-
cantly facilitates the anti-immobility effect of the 5-HT1B receptor
agonist in the tail suspension test (Chen et al., 2011). In this
behavioral test, low doses of GSK3 inhibitors and anpirtoline are
used so that GSK3 inhibitors alone has no effect and anpirto-
line alone only mildly reduces the immobility, which highlights
the combination effect of GSK3 inhibition and 5-HT1B recep-
tor activation. Finding of this study suggests that GSK3 inhibitors
facilitate the anti-immobility effect of 5-HT1B heteroreceptors by
abolishing 5-HT1B autoreceptor-mediated inhibition of serotonin
release. Interestingly, the anpirtoline-induced increase in horizon-
tal locomotor activity was not altered by GSK3 inhibitors, but
is largely diminished in β-arrestin2-knockout mice (Chen et al.,
2011), which is in agreement with the in vitro ﬁndings showing
that association of β-arrestin2 with 5-HT1B receptors does not
depend on GSK3β. Therefore, these initial behavior data further
suggest that GSK3 has differential effects in modulating 5-HT1B
receptor functions in brain.
Taken together, molecular and in vivo studies support a promi-
nent effect of GSK3β to selectively regulate 5-HT1B receptor
function (Figure 4). The effect of GSK3β is elicited by directly
interacting with 5-HT1B receptors at the intracellular loop-2. This
interaction functions to facilitate 5-HT1B receptor-regulated Giα-
mediated signaling. In the absence of GSK3β, 5-HT1B receptors
are dissociated from the conventional Giα-mediated signaling, but
still able to respond to agonist-induced recruitment of β-arrestin2
and receptor internalization. Regulation of 5-HT1B receptors
by GSK3β has functional signiﬁcance since it impacts 5-HT1B
receptor-dependent 5-HT release. Although this and other phys-
iological functions of the highly selective modulation of 5-HT1B
receptors by GSK3β remain to be investigated in further detail,
initial evidence supports a signiﬁcant behavioral impact of this
GSK3 action that may be important for therapeutic development.
Several important questions remain to be addressed before the
importance of this unique effect of GSK3β is completely elu-
cidated. Particularly important is to understand if the effect of
GSK3β is selective to 5-HT1B autoreceptors only or both auto-
and hetero-receptors, which 5-HT1B receptor-regulated signaling
mechanisms in the brain are affected by GSK3β, and if the GSK3β-
dependent signaling pathways correlate with the effect of GSK3β
on the physiological and behavioral functions of brain 5-HT1B
receptors.
SUMMARY
Cumulative evidence from in vitro measurements, pharmacologi-
cal studies, and animal behavioral tests strongly support GSK3 as
an integrative mediator of 5-HT neurotransmission. First, GSK3
is an early intracellular responder to a surge of brain 5-HT,
which results in GSK3 phosphorylation at an N-terminal serine
and inactivation of its constitutive activity. Phosphorylation of
GSK3 by increasing brain 5-HT may be therapeutically impor-
tant as the behavioral effect of ﬂuoxetine is mediated by GSK3
phosphorylation. Second, GSK3 is a down-stream target of 5-
HT1A receptor signaling, and enhancing GSK3 phosphorylation
by 5-HT1A receptors in the hippocampus is associated with its
inhibitory effect on contextual fear learning. Third,5-HT2A recep-
tors elicit sophisticated regulatory effect on GSK3, as both agonist
and antagonist of 5-HT2A receptors may inactivate it, but the
effects likely depend on the receptor activation state and the pres-
ence of other receptor interactive proteins. Regulation of GSK3 by
5-HT2A receptors may have therapeutic implication as evidenced
by the prominent inhibitory effect of atypical antipsychotics on
GSK3, presumably related to the 5-HT2A receptor antagonistic
effect of these drugs. Finally, GSK3β interacts with and modu-
lates 5-HT1B receptor activity in a receptor subtype- and signaling
pathway-selective manner. Although the physiological impact of
this action in intact brain remains to be elucidated, it is predicted
that this action of GSK3β is to rapidly reset the level of 5-HT in
certain brain areas to ameliorate prolonged effect of 5-HT,whereas
the therapeutic implication of this unique action of GSK3 remains
to be further studied.
The prominent effect of GSK3 on serotonin neurotransmis-
sion may partially explain the many ﬁndings of behavioral actions
of GSK3 as well as it being a converging target of mood stabi-
lizers, antidepressants, and antipsychotics (Li and Jope, 2010).
Integrating 5-HT neurotransmission by GSK3 may be particu-
larly indicative in the pathophysiological roles of GSK3 in mood,
anxiety, and cognitive disorders that involve dysregulation of 5-HT
neurotransmission, and in the therapeutics targeting GSK3 for the
treatment of these diseases.
However, our current knowledge on this potentially important
function of GSK3 is limited.GSK3has only been found to associate
with 5-HT1A, 5-HT1B, and 5-HT2A receptors. Evidence showing
GSK3as a down-stream target or amodulator of other 5-HTrecep-
tor subtypes is still lacking. As discussed in this review, the two
isoforms of GSK3 appear to have common and unique relations
to different 5-HT receptors, but it is not yet clear if the divergent
relationship is receptor subtype- or brain region-speciﬁc. Addi-
tional investigations are also necessary to fully understand how
altered activity of GSK3 affects 5-HT-regulated behaviors, and to
determine the mechanisms of how each behavior is affected by
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FIGURE 4 | Proposed effects of GSK3β in regulating 5-HT1B
receptor-coupled signal transduction, 5-HT1B
receptor-regulated 5-HT release, and 5-HT1B
receptor-regulated behaviors. α, β, γ, G-protein subunits; AC, adenylyl
cyclase; β-arr, β-arrestin; Gi, G-protein; GSK3, glycogen synthase kinase-3;
5HT, serotonin; 1AR, 1BR, 2AR, serotonin receptor subtypes; P,
phosphorylated; PDK, phosphoinositide-dependent kinase-1; PI3K,
phosphatidylinositol-3-kinase.
altered GSK3 activity. Since GSK3 is a protein kinase, an impor-
tant task is to identify speciﬁc protein substrates that mediate the
divergent physiological and behavioral effects of GSK3 within and
beyond 5-HT neurotransmission. Human studies are needed to
determine if clinical ﬁndings support the ample preclinical evi-
dence suggesting a role of GSK3 in 5-HT dysregulation and related
brain disorders. Finally, all the ongoing and future research tasks
should converge to developing GSK3 modulators that are able
to substitute, facilitate, or supplement therapeutic drugs that are
known to modulate 5-HT neurotransmission.
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